Much effort has been devoted to understand how chromatin modification regulates development and disease. Despite recent progress, however, it remains difficult to achieve high sensitivity and reliability of chromatin-immunoprecipitation-coupled deep sequencing (ChIP-seq) to map the epigenome and global transcription factor binding sites in cell populations of low cell abundance. We present a new Atlantis dsDNase-based technology, aFARP-ChIP-seq, that provides accurate profiling of genome-wide histone modifications in as few as 100 cells. By mapping histone lysine trimethylation (H3K4me3) and H3K27Ac in group I innate lymphoid cells from different tissues, aFARP-ChIP-seq uncovers potentially distinct active promoter and enhancer landscapes of several tissue-specific NK and ILC1. aFARP-ChIP-seq is also highly effective in mapping transcription factor binding sites in small number of cells.
Introduction
ROC curve (AUC) is a standard metric for quantifying balanced sensitivity and specificity. By using different cutoffs to calculate the true-positive and false-positive rates, we plotted ROC curves for each method, which showed that aFARP-ChIP-seq using 100 or 500 cells provides reliable performances ( Figure 2D ). These analyses demonstrate that aFARP-ChIP-seq enables analysis of as few as 100 cells.
The H3K4me3 profiling of group 1 innate lymphocyte lineages reflects their distinct functionalities
To test the applicability of aFARP-ChIP-seq, we applied it on challenging in vivo biological samples by profiling histone modifications in innate lymphoid cell (ILC) types, which typically make up 1-5 % of total lymphocytes in peripheral non-gut tissues (Diefenbach et al., 2014) . Recent studies indicate that tissue-specific signals have significant impacts on gene expression and activity of ILCs. The influence of local tissue microenvironments on chromatin and gene regulatory landscapes, however, has remained not well understood (Gury-BenAri et al., 2016a; Shih et al., 2016; Sciumè et al., 2017) , in part, due to the difficulty in mapping chromatin and gene regulatory landscapes in ILCs isolated from individual animals. We focused our study on the IFN-γ-producing group 1 ILCs, including conventional NK and ILC1, isolated from individual mice (Cortez and Colonna, 2016) Since there is a lack of unique and consistent markers in NK cells and ILC1 cells in various organs, we used different sorting strategies according to previously published protocols for each tissue, including spleen, mesenteric lymph nodes (mLN), liver and small intestine intraepithelia ( Figure 3A and Figure S2A ) (Robinette et al., 2015) . We then applied aFARP-ChIP-seq to profile H3K4me3 using NK or ILC1 sorted from each tissue from one mice without further in vitro culturing. For each aFARP-ChIP-seq analyses, we used 1000-2000 cells that were estimated based on the cell numbers sorted by Fluorescence Activated Cell Sorting (FACS). We found consistent maps for H3K4me3 between biological replicates in the ILC1 and NK cells in different tissues, which allowed us to examine the chromatin landscapes in these two group 1 ILC sub-lineages.
We identified 789 up-and 271 down-regulated H3K4me3 peaks in spleen, 604 up-and 557 down-regulated peaks in mLN, and 966 up-and 490 down-regulated H3K4me3 peaks in liver in ILC1 compared to NK cells (fold change > 1.5, FDR < 0.05.) ( Figure 3B-D) . We found those exhibiting differentially H3K4me3 peaks correlated with the lineage-specific developmental program and functionality of each subset such as IL7r (ILC1), Eomes (NK), and Gzma (NK, cytotoxic machinery) ( Figure 3E ).
Specifically, the H3K4me3 levels on Eomes is greater than twofold in NK cells than in ILC1 cells in all tissues analyzed ( Figure 3E and Table S1 ), which is consistent with previous finding that Emoes is a marker for NK cells (Gordon et al., 2012; Daussy et al., 2014; Zhang et al., 2018) . Interestingly, we found that siIEL ILC1 isolated from small intestines exhibited H3K4me3 peaks on both IL7r and Eomes ( Figure 3E ). This suggests functional plasticity of this unique ILC1 probably due to their constant exposure to varied environmental signals from microbiome and nutrients in the gut.
The Multi-Dimensional Scaling (MDS) plot also revealed that siIEL ILC1 to be distinct from both ILC1 and NK derived from different peripheral tissues ( Figure 3F ). The elevated H3K4me3 peak in TGF-β locus in siIEL ILC1 compared to NK and other ILC1 cells ( Figure 3G ) is consistent with the unique roles of TGF-β in the development and function of siIEL ILC1 (Robinette et al., 2015; Cortez et al., 2016) H3K27Ac mapping reveals differential enhancer landscapes in the siIEL ILC1 compared to the other ILC1 It is well known that gene expression programs in ILC subsets in different tissues can reflect distinct patterns of enhancer activity that in turn reflects the differential transcription factor binding profiles (Hallikas et al., 2006; Spitz and Furlong, 2012; Heinz et al., 2015) . To probe the regulatory circuitry that specifies siIEL ILC1 and its functions, we next mapped the active enhancer mark H3K27Ac (Creyghton et al., 2010) in the same set of NK and ILC1 isolated from individual mice as described above (see Figure 3 and S2) using estimated 1000-2000 cells (based on FACS sorting) for each ChIP-seq experiment. The biological replicates of our maps were highly consistent with one another ( Figure 4A and Figure S3A-F) . We then focused on analyzing the active enhancers in ILC1 from spleen, lymph nodes, liver, and small intestine. We identified total 21417 enhancers that are active in at least one ILC1 cell type from at least one of the four tissues profiled ( Figure 4B and Table S2 ).
Consistent with previous finding of an early developmental acquisition of common chromatin organization in ILCs (Shih et al., 2016) , the ILC1 cells from siIEL shared 9892 enhancers with the other ILC1 from spleen, lymph node, and liver ( Figure 4B ).
We also identified 2100 enhancers that are unique to siIEL ILC1 ( Figure 4B ). By analyzing the top five genes located most proximally to the up-regulated enhancers in the siEIL ILC1 (compared to the other three ILC1), we found Ahrr, Cnih3
( Figure 4C and Figure S3G ), Ccny, Sec24d, and Rin2. Interestingly, a recent study reported that the expression of AhRR in colonic intraepithelial lymphocytes prevents excessive IL-1β production and Th17/Tc17 differentiation, implicating the physiologic importance of AhRR in balancing intestine inflammation (Brandstätter et al., 2016) .
Our finding that Ahrr gene is marked strongly by active enhancers in siIEL ILC1
suggests that siEIL ILC1 could also use Ahrr in modulating inflammation in the small intestines. Our analyses also indicate that the other genes, such as Cnih3 and Ccny, could also play important roles in siEIL ILC1. Although additional studies are required to validate this possibility, the high-quality enhancer profiling achieved using aFARP-ChIP-seq in small number of cells directly isolated from tissues should facilitate the identification of candidate genes that function in lineage specification or functional plasticity of cells in vivo such as the ILC1 subsets in different tissue microenvironments in individual mice.
Since transcription factor binding is a key determinant of enhancer activity, we next attempted to identify potential transcription factors that could regulate the enhancer landscape in siEIL ILC1 by searching for the enrichment of transcription factor binding motifs in H3K27Ac peaks identified in these cells. This allowed the identified a full set of transcription factor signatures of siEIL ILC1. Among these, we found significant enrichment of sequence motifs known to be bound by Fli1 (or ETS), IRF1, RunX1, Zfx and Gata3 ( Figure 4D ), which have been shown to play important roles for the development and function of ILC1 in general (Rankin et al., 2013; Diefenbach et al., 2014; Tanriver and Diefenbach, 2014) . These results suggest that the shared transcriptional regulatory elements underlying either development or functionality of ILC1 subpopulations across the different tissue origins. Together, our analyses show that the high quality H3K4me3 and H3K27Ac datasets we generated for NK and ILC1 in different tissues can serve as valuable resources. (encoding Bruton tyrosine kinase), and Fcgr2b (encoding FcγRIIb), and our parallel mapping using isolated T cells showed that these genes do not have PU.1 binding as expected ( Figure 5A and Figure S4 ) (Schweitzer et al., 2006; Xu et al., 2012; Solomon et al., 2015) . Additionally, we observed a similar PU.1 binding pattern around TNF locus as those obtained using iChIP-seq in 1x 10 4 dendritic cells derived by in vitro differentiation of mouse bone marrow cells ( Figure 5B ) (Lara-Astiaso et al., 2014) .
aFARP-ChIP
To further validate the results of our aFARP-ChIP-seq in the isolated splenic B cells, we screened for the sequences of the enriched read regions for potential transcription factor binding motifs. We found that the top motif for PU.1-bound regions contain a canonical ETS motif, 5′ -GGAA-3′ ( Figure 5C ) (Solomon et al., 2015) .
Therefore, the reproducibility and sensitivity of aFARP-ChIP-seq should allow genome wide characterization of chromatin binding proteins including transcription factors in small number of cells directly sorted from tissues.
Discussion
By searching for DNases that allow reliable chromatin fragmentation under wider range of conditions than the commonly used MNase, we found that the Atlantis dsDNase can fragment chromatin reproducibly in different cell types and in different number of cells using a relatively wide range of incubation time without over digesting chromatin. Thus, the Atlantis dsDNase is a superior choice over MNase in applications involving chromatin fragmentation.
By applying FARP-ChIP-seq on the Atlantis dsDNase generated chromatin (aFARP-ChIP-seq), we are able to produce high-quality ChIP-seq datasets in as few as 100 cells. We have shown that addition of carriers in FARP-ChIP-seq allows capture of low abundance chromatin without excessive PCR amplification, thereby greatly improves the fidelity and reproducibility of genome-wide chromatin mapping in small number of cells. However, a ~5-fold increase of sequencing depth is required to obtain sufficient reads of interest by FARP-ChIP-seq (Zheng et al., 2015) , which increases sequencing costs. The improved chromatin fragmentation by Atlantis DNase in aFARP-ChIP-seq greatly increased the recovery of low abundance chromatin compared to FARP-ChIP-seq. Indeed, we show that aFARP-ChIP-seq offers a ~3-fold increase of DNA reads compared to FARP-ChIP-seq at the same read depth for Rotem et al., 2015) .
Considering the aFARP-ChIP-seq is fundamentally different from other high-sensitivity ChIP technologies, which rely on either excessive DNA amplification or chromatin indexing, we believe that it offers a viable alternative approach to further reduce read depth and cell number needed in a high throughout format.
By sorting the group 1 ILC subsets in mesenteric lymph node (mLN), spleen, small intestine, and liver from one mouse, we obtained high quality mapping of We also observed pronounced epigenome differences in siIEL ILC1 isolated from small intestine's intraepithelial compartment compared to the ILC1s from the other three tissues we analyzed, which is consistent with the recently reported transcriptome differences in the group I ILCs (Robinette et al., 2015) . Interestingly, we
show that siIEL ILC1 exhibits H3K4me3 peaks on Eomes, a key lineage-determining transcription factor for NK cells. One explanation for this finding is that the siIEL ILC1
identified by cell-surface markers (NKp46+NK1.1+) is a heterogeneous population and it may be composed of both unidentified NK subsets and ILC1 lineage in the gut intraepithelial compartment. Alternatively, these siIEL ILC1 may exhibit lineage and functional plasticity due to the unique gut environment. Consistently, an ILC3-derived 
Materials and methods

Cell lines and animals
E14 mouse embryotic stem cells (mESCs) were cultured in DMEM with 15% fetal calf serum, penicillin/streptomycin, β-mercaptoethanol, L-glutamine, nonessential amino acids, recombinant leukemia inhibitory factor (1000 U/ml, Millipore). See also Figure S1 . See also Figure S2 and Table S1 
